BACKGROUND: To obtain insight into the age-specific seroprevalence for seven high-risk human papillomavirus (hr-HPV) serotypes (HPV16, 18, 31, 33, 45, 52, and 58) among the general population in the pre-vaccination era in The Netherlands. METHODS: From a cross-sectional population-based study (ISRCTN 20164309) performed in 2006/2007 6384 sera of men, women and children were tested for seven hr-HPV specific antibodies using a fluorescent bead-based multiplex immunoassay with virus-like particles of the seven HPV serotypes. RESULTS: An increase in seroprevalence was observed in adolescents, especially for the most prevalent HPV type 16 (up to 11.3%). The increase was most pronounced in women, but was less clear for the other six HPV serotypes. Relatively stable seroprevalences were found in the middle aged cohorts and a slight decrease in the elderly. For the age cohorts >14 years, the seroprevalence among women (25.2%) was higher compared with men (20.3%) (p=0.0002). We found that 10.1% of the population was seropositive for multiple HPV serotypes. CONCLUSIONS: The HPV vaccination program is targeted at preadolescents as is justified by the results in this study in which a step-up in HPV seroprevalence is observed at ages of sexual debut. Although direct interpretation of seroprevalence data are hampered by cross-reactivity and seroconversion rate, these data are useful as baseline to evaluate long-term population effects of the HPV16/18 vaccination program.
BACKGROUND: To obtain insight into the age-specific seroprevalence for seven high-risk human papillomavirus (hr-HPV) serotypes (HPV16, 18, 31, 33, 45, 52, and 58) among the general population in the pre-vaccination era in The Netherlands. METHODS: From a cross-sectional population-based study (ISRCTN 20164309) performed in 2006/2007 6384 sera of men, women and children were tested for seven hr-HPV specific antibodies using a fluorescent bead-based multiplex immunoassay with virus-like particles of the seven HPV serotypes. RESULTS: An increase in seroprevalence was observed in adolescents, especially for the most prevalent HPV type 16 (up to 11.3%). The increase was most pronounced in women, but was less clear for the other six HPV serotypes. Relatively stable seroprevalences were found in the middle aged cohorts and a slight decrease in the elderly. For the age cohorts >14 years, the seroprevalence among women (25.2%) was higher compared with men (20.3%) (p=0.0002). We found that 10.1% of the population was seropositive for multiple HPV serotypes. CONCLUSIONS: The HPV vaccination program is targeted at preadolescents as is justified by the results in this study in which a step-up in HPV seroprevalence is observed at ages of sexual debut. Although direct interpretation of seroprevalence data are hampered by cross-reactivity and seroconversion rate, these data are useful as baseline to evaluate long-term population effects of the HPV16/18 vaccination program.
Authors: Mirte Scherpenisse; Madelief Mollers; Rutger M Schepp; Chris J L M Meijer; Hester E de Melker; Guy A M Berbers; Fiona R M van der Klis Journal: Hum Vaccin Immunother Date: 2012-11-13 Impact factor: 3.452
Authors: Patricia Sadate-Ngatchou; Joseph J Carter; Stephen E Hawes; Qinghua Feng; Taylor Lasof; Joshua E Stern; Tsung-Chieh Jane Fu; Denise A Galloway; Laura A Koutsky; Rachel L Winer Journal: Sex Transm Dis Date: 2016-03 Impact factor: 2.830
Authors: Mirte Scherpenisse; Rutger M Schepp; Madelief Mollers; Sofie H Mooij; Chris J L M Meijer; Guy A M Berbers; Fiona R M van der Klis Journal: Clin Vaccine Immunol Date: 2013-06-05
Authors: Aaron C Ermel; Marcia L Shew; Bree A Weaver; Brahim Qadadri; Cheryl Denski; Wanzhu Tu; Yan Tong; J D Fortenberry; Darron R Brown Journal: Sex Transm Infect Date: 2013-09-12 Impact factor: 3.519
Authors: Mirte Scherpenisse; Rutger M Schepp; Madelief Mollers; Chris J L M Meijer; Guy A M Berbers; Fiona R M van der Klis Journal: PLoS One Date: 2013-09-18 Impact factor: 3.240
Authors: Vera M van Rijn; Sofie H Mooij; Madelief Mollers; Peter J F Snijders; Arjen G C L Speksnijder; Audrey J King; Henry J C de Vries; Arne van Eeden; Fiona R M van der Klis; Hester E de Melker; Marianne A B van der Sande; Maarten F Schim van der Loeff Journal: PLoS One Date: 2014-03-20 Impact factor: 3.240
Authors: Mirte Scherpenisse; Madelief Mollers; Rutger M Schepp; Hein J Boot; Chris J L M Meijer; Guy A M Berbers; Fiona R M van der Klis; Hester E de Melker Journal: PLoS One Date: 2012-11-12 Impact factor: 3.240
Authors: Henrike J Vriend; Johannes A Bogaards; Fiona R M van der Klis; Mirte Scherpenisse; Hein J Boot; Audrey J King; Marianne A B van der Sande Journal: PLoS One Date: 2013-04-23 Impact factor: 3.240
Authors: A P Ortiz; E R Unger; C Muñoz; G Panicker; G Tortolero-Luna; M Soto-Salgado; Y Otero; E Suárez; C M Pérez Journal: BMJ Open Date: 2014-02-04 Impact factor: 2.692
Authors: Felipe A Castro; Angelica Dominguez; Klaus Puschel; Vanessa Van De Wyngard; Peter J F Snijders; Silvia Franceschi; Michael Pawlita; Catterina Ferreccio Journal: BMC Infect Dis Date: 2014-07-03 Impact factor: 3.090